Brightintel secures tens of millions in Pre-A funding as Phase III trial for long-acting analgesic nears

Brightintel Bioscience completed a tens of millions of yuan Pre-A funding round in the first half of 2025. This round was led by an industry-focused fund, with several existing institutional shareholders participating. The proceeds will primarily support the clinical advancement of the company's core product, GBI268, and technological upgrades to its AI-powered drug discovery platform. This continued capital injection reflects strong market confidence in Brightintel's R&D potential and industrial prospects in the non-opioid analgesic field.

The pain treatment sector targeted by Brightintel represents a massive market with sustained demand growth—a trillion-yuan-level industry. Data indicates that the global analgesic market has reached US$100 billion, while China's analgesic market has grown to RMB 122.6 billion, demonstrating the vast potential of this therapeutic area.

Brightintel Bioscience was co-founded by two core figures with profound expertise in drug development and AI science: Dr. Yue Feng and Dr. Fang Jiansong. The professional backgrounds and capabilities of the two founders are highly synergistic and complementary, collectively forming a complete capability chain spanning from drug discovery to industrial implementation.

Dr. Yue Feng, Founder and CEO, has long focused on the R&D and industrialization of anesthetics and analgesics, possessing over ten years of experience in the pharmaceutical industry. Dr. Fang Jiansong, Co-founder and Chief Scientific Officer, has deep academic accomplishments in pharmacology and drug discovery, having been consecutively recognized six times in the global Top 2% of Scientists list. His research emphasizes AI and network medicine-driven drug discovery.

Leveraging the founders' professional strengths, Brightintel has established a unique technology platform system dedicated to achieving breakthroughs in pain treatment. To this end, the company has conducted in-depth exploration in two critical technologies: AI-based drug design and efficient drug delivery systems.

Leveraging its robust technology platform, Brightintel Bioscience focuses on the pain treatment sector, with a clear near-term emphasis on the clinically urgent segment of post-operative analgesia. The company has established a well-defined product pipeline, including its core asset GBI268, and investigational drugs GBI168 and GBI005.

Among these, the GBI268 project has progressed particularly rapidly, having already completed a Phase II clinical trial. The trial yielded better-than-expected results, demonstrating potent and sustained analgesic efficacy. GBI268 showed significant superiority compared to both the placebo and active comparator groups. The company anticipates promptly initiating a Phase III clinical trial for this product.

Currently, driven by AI-powered R&D and formulation innovation, Brightintel has established a preliminary closed-loop integration of technology, products, and clinical development in the non-opioid analgesic field. From scientific breakthrough and clinical validation to capital recognition, Brightintel is creating new possibilities for global pain treatment through its "Innovated in China" approach.